Entera Bio Q2 EPS misses estimate as net loss widens to $7.3 million

Entera Bio Ltd. (NASDAQ: ENTX) reported Q2 2026 EPS loss of $0.14 versus a $0.08 consensus estimate, with net loss widening to $7.3 million from $2.7 million a year earlier, driven mainly by a $2.7 million non-cash warrant fair value remeasurement. The company also closed an oversubscribed $275 million private placement to fund EB613 Phase 3 NDA work through 2030.

Original reporting
Published Aug 8, 2026, 2:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 8, 2026, 8:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Entera Bio Q2 EPS misses estimate as net loss widens to $7.3 million — source image
Decision brief

The 30-second read

$ENTXNeutralMed
01

Why it matters

The key trade inputs are (1) the Q2 earnings miss driven by non-cash warrant remeasurement, (2) a large oversubscribed $275M private placement that extends runway, and (3) confirmation of alignment with the FDA on Phase 3 study design, plus selected Phase 2 post-hoc data for ASBMR 2026 presentations.

02

Market read

Traders can reassess ENTX risk after a large, time-specific financing event and FDA-aligned Phase 3 design confirmation, despite a headline EPS miss.

03

What to watch

The article emphasizes funding and design alignment, but does not provide Phase 3 enrollment timelines, interim readouts, or specific NDA filing milestones beyond 'through 2030,' which could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: post-market/early pre-open context for Aug 8, 2026 trading decisions

Background

Entera Bio is advancing EB613, an oral anabolic tablet for postmenopausal osteoporosis, toward a registrational Phase 3 and potential NDA.

Company-level read

Ticker impact

$ENTXNeutralMedium confidence
Context

Entera Bio missed Q2 EPS ($0.14 vs $0.08) as net loss widened to $7.3M, while simultaneously closing an oversubscribed $275M private placement to fund EB613 through NDA submission.

Expected impact

Near-term volatility likely, with downside risk from the EPS miss offset by upside from the $275M raise and FDA alignment.

Evidence & confidence

The article provides a concrete earnings datapoint and a large, time-specific financing event, plus a stated FDA alignment on Phase 3 design and a Phase 2 data presentation selection.

Market effects

Biotech financing and osteoporosis pipeline sentiment may be influenced by evidence of continued investor appetite for late-stage preparatory funding.

Limited, as the company is Tel Aviv-based but the catalysts are US FDA and US-listed financing.

Moderate, since osteoporosis and oral anabolic therapy development can affect broader investor narratives around oral alternatives to injectables.

Counterpoint

The EPS miss is largely non-cash warrant remeasurement, so the market may overreact to the headline loss while underweighting the cash runway and FDA alignment.

Key entities

  • Entera Bio Ltd.

    NASDAQ-listed biotech advancing EB613 toward NDA submission; reported Q2 loss and raised $275M via private placement.

  • EB613

    Oral anabolic tablet for osteoporosis in postmenopausal women; Phase 3 registrational program funded through NDA submission.

  • OPKO Health Inc.

    Collaboration partner referenced for EB612 clinical activities and IND timing.

  • BVF Partners L.P.

    Lead participant in the oversubscribed $275M private placement, with right to designate two directors.

  • U.S. Food and Drug Administration (FDA)

    Confirmed alignment with Entera on registrational Phase 3 study design for EB613.

Related articles

$ENTXMedAI 8/10

A planned osteoporosis pill trial is expected to enroll about 900 women. Entera expects its first site to open in late 2026.

Entera Bio (ENTX) plans to initiate a Phase 3 trial for its osteoporosis drug EB613 in late 2026, with 900 women expected to enroll. The company presented Phase 2 data at ASBMR 2026, showing potential benefits for patients with low bone mineral density. Entera also announced key leadership appointments and financial results for Q3 2026.

$ENTXMedAI 8/10

Entera Bio to present Phase 3 trial design for oral osteoporosis drug

Entera Bio (ENTX) will present Phase 3 trial design for its oral osteoporosis drug, EB613, at a conference in October 2026. The study will evaluate EB613 in postmenopausal women with osteoporosis. The company previously reported positive Phase 2 results, showing improvements in bone density and markers. EB613 is an oral, once-daily tablet, unlike current anabolic therapies that require injections.

$ENTXMed

Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)

Entera Bio (ENTX) received an 'Outperform' rating and $9 price target from Leerink Partners. The company's lead drug, EB613, is in development for osteoporosis and has completed Phase 2 trials. Entera recently raised $275M in funding and plans to initiate Phase 3 trials in late 2026, with data expected in 2028. ENTX was trading at $3.03 per share as of September 17, 2026.